1-3 of 3
Kathy A Reichel
Close
Sort by
Journal Articles

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma

Dipenkumar Modi, Seongho Kim, Silva Pregja, Christiane Houde, Kathy A. Reichel, Rod Ramchandren
Journal: Blood
Blood (2021) 138 (Supplement 1): 3561.
https://doi.org/10.1182/blood-2021-149793
Published: 2021
Journal Articles

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Vishal Kukreti, MD FRCP(C), Sascha A Tuchman, MD, Yubin Kang, MD, Divaya Bhutani, MD, Steven Burt, ANP, Christiane Houde, BS, Kathy A. Reichel, Silva Pregja, MBA, Jeffrey V Matous, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3158.
https://doi.org/10.1182/blood.V130.Suppl_1.3158.3158
Published: 2017
Journal Articles

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Jeffrey Zonder, MD, Christiane Houde, BS, Sascha Tuchman, MD, Vishal Kukreti, MD, Vaishali Sanchorawala, MD, Silva Pregja, MBA, Kathy A Reichel, Steven M Burt, NP, Colleen Neveux, RN, Jeffrey Matous, MD
Journal: Blood
Blood (2014) 124 (21): 4767.
https://doi.org/10.1182/blood.V124.21.4767.4767
Published: 2014